Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Godkin

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Scientific Reports|September 7, 2012
Minimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimersChristopher J Holland, Pierre J Rizkallah, Sabrina Vollers, et al.
European Journal of Immunology|June 2, 2012
Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+ T-cell immunityTom Pembroke, Ian Rees, Kathleen Gallagher, et al.
Cancer Immunology Research|January 11, 2014
Escalating regulation of 5T4-specific IFN-γ<sup>+</sup> CD4<sup>+</sup> T cells distinguishes colorectal cancer patients from healthy controls and provides a target for <i>in vivo</i> therapyMartin Scurr, Anja Bloom, Tom Pembroke, et al.
International Journal of Cancer|October 22, 2013
Progression of carcinogen-induced fibrosarcomas is associated with the accumulation of naïve CD4+ T cells via blood vessels and lymphaticsBeatrice Ondondo, Emma Jones, James Hindley, et al.
Nature Communications|September 21, 2022
Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunityMartin J Scurr, George Lippiatt, Lorenzo Capitani, et al.
Cancer Immunology Research|September 27, 2017
Treg Depletion Licenses T Cell-Driven HEV Neogenesis and Promotes Tumor DestructionEmily J Colbeck, Emma Jones, James P Hindley, et al.
Cell Reports|July 20, 2023
Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4<sup>+</sup> T cell immunityYuan Chen, Georgina H Mason, D Oliver Scourfield, et al.
BMC Gastroenterology|June 22, 2019
The Ussing chamber system for measuring intestinal permeability in health and diseaseAmanda Thomson, Kathryn Smart, Michelle S Somerville, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2017
Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal CancerMartin Scurr, Tom Pembroke, Anja Bloom, et al.
The Journal of Biological Chemistry|October 18, 2019
Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitopeBruce J MacLachlan, Garry Dolton, Athanasios Papakyriakou, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Scientific Reports|September 7, 2012
Minimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimersChristopher J Holland, Pierre J Rizkallah, Sabrina Vollers, et al.
European Journal of Immunology|June 2, 2012
Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+ T-cell immunityTom Pembroke, Ian Rees, Kathleen Gallagher, et al.
Cancer Immunology Research|January 11, 2014
Escalating regulation of 5T4-specific IFN-γ<sup>+</sup> CD4<sup>+</sup> T cells distinguishes colorectal cancer patients from healthy controls and provides a target for <i>in vivo</i> therapyMartin Scurr, Anja Bloom, Tom Pembroke, et al.
International Journal of Cancer|October 22, 2013
Progression of carcinogen-induced fibrosarcomas is associated with the accumulation of naïve CD4+ T cells via blood vessels and lymphaticsBeatrice Ondondo, Emma Jones, James Hindley, et al.
Nature Communications|September 21, 2022
Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunityMartin J Scurr, George Lippiatt, Lorenzo Capitani, et al.
Cancer Immunology Research|September 27, 2017
Treg Depletion Licenses T Cell-Driven HEV Neogenesis and Promotes Tumor DestructionEmily J Colbeck, Emma Jones, James P Hindley, et al.
Cell Reports|July 20, 2023
Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4<sup>+</sup> T cell immunityYuan Chen, Georgina H Mason, D Oliver Scourfield, et al.
BMC Gastroenterology|June 22, 2019
The Ussing chamber system for measuring intestinal permeability in health and diseaseAmanda Thomson, Kathryn Smart, Michelle S Somerville, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2017
Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal CancerMartin Scurr, Tom Pembroke, Anja Bloom, et al.
The Journal of Biological Chemistry|October 18, 2019
Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitopeBruce J MacLachlan, Garry Dolton, Athanasios Papakyriakou, et al.
Pageof 7